SYNC.L

Syncona Limited NPV
Syncona Limited - Transaction in Own Shares
2nd May 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8999M
Syncona Limited
02 May 2024
 

2 May 2024

Syncona Limited

("Syncona" or the "Company")

Transaction in Own Shares

Syncona, a leading healthcare company focused on creating, building and scaling global leaders in life science announces that, in accordance with the terms of its share buyback programme announced on 29 September 2023 (the "Share Buyback Programme"), the Company purchased the following number of its ordinary shares of no par value ("Ordinary Shares") each through Numis Securities Limited ("Numis").

Date of purchase:

1 May 2024

Aggregate number of Ordinary Shares purchased:

140,000

Lowest price paid per share (GBp):

122.3571

Highest price paid per share (GBp):

122.3571

Volume weighted average price paid per share (GBp):

122.3571

 

The repurchased Ordinary Shares will be held by the Company in treasury. Following the purchase and settlement of these Ordinary Shares, the Company's issued ordinary share capital is 671,806,666 of which 19,331,080 Ordinary Shares will be held in treasury, which attract no voting rights. Therefore, the total voting rights in the Company will be 652,475,586. This figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 which forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Numis as part of the Share Buyback Programme.

 

Individual information:

 

Numbers of shares purchased

Transaction price (pence per share)

Time of transaction

Venue

140,000

122.3571

16:40.02

XLON

 

For further information, please contact:

Syncona Ltd

Annabel Clark 

Tel: +44 (0) 7714 916615

  

Numis Securities Limited

Nathan Brown

Freddie Barnfield

Tel: +44 (0) 7260 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSABMFTMTJMBAI]]>
TwitterFacebookLinkedIn